We are live on ! Find out more
LFCR icon

Lifecore Biomedical

109 hedge funds and large institutions have $338M invested in Lifecore Biomedical in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 48 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

13% more capital invested

Capital invested by funds: $301M → $338M (+$37.8M)

2% more funds holding

Funds holding: 107109 (+2)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

42% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 48

Holders
109
Holders Change
+2
Holders Change %
+1.87%
% of All Funds
2.91%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
14
Increased
28
Reduced
48
Closed
10
Calls
$22K
Puts
Net Calls
+$22K
Net Calls Change
+$18K

LFCR Hedge Fund Activity: Q4 2014 in Review

109 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2014, worth a combined $338M — up 13% from $301M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LFCR positions and 10 closed out — a net gain of 4 holders — while 28 added to existing stakes and 48 trimmed.

The largest buyer was NWQ Investment Management Company, adding an estimated $6.16M. The largest seller was Guggenheim Capital, cutting an estimated $6.97M.

  • 109 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2014, up from 107 in Q3 2014.
  • Funds reported $338M of Lifecore Biomedical stock for Q4 2014, up 13% quarter-over-quarter.
  • 14 funds opened new Lifecore Biomedical positions in Q4 2014 and 10 closed out, a net change of +4 holders.
  • The largest Lifecore Biomedical buyer in Q4 2014 was NWQ Investment Management Company, an estimated $6.16M added.
  • The largest Lifecore Biomedical seller in Q4 2014 was Guggenheim Capital, an estimated $6.97M sold.

Based on aggregated 13F filings for Q4 2014.